类风湿关节炎随机对照试验对老年患者的排除
该分析纳入2013至2022年间在ClinicalTrials.gov注册的290项类风湿关节炎药物随机对照试验,发现143/290(49%)设有85岁或以下年龄上限,154/290(53%)至少有一项间接排除老年人的入选标准,217项(75%)明确或间接排除老年患者,仅1项(0.3%)仅纳入65岁及以上患者。
要点
- 143/290(49%)项试验设有85岁或以下年龄上限。
- 154/290(53%)项试验至少有一项间接排除老年人的标准。
- 仅1项(0.3%)试验仅纳入65岁及以上患者。
核心结论
- 老年成人常因年龄上限和其他入选标准被排除在类风湿关节炎随机对照试验之外,这严重限制了临床实践中老年患者治疗的证据基础。
研究设计与样本
- 分析纳入ClinicalTrials.gov注册且于2013至2022年间启动的类风湿关节炎药物干预随机对照试验,共290项。
主要发现
- 143/290(49%)项试验设有85岁或以下年龄上限。
- 多变量分析显示,设有年龄上限的 odds 在美国进行的试验中显著更低(aOR 0.34;CI 0.12-0.99;P = 0.04),在洲际试验中也显著更低(aOR 0.4;CI 0.18-0.87;P = 0.02)。
- 154/290(53%)项试验至少有一项间接排除老年人的入选标准,包括特定合并症(n = 114;39%)、依从性顾虑(n = 67;23%)以及宽泛模糊的排除标准(n = 57;20%),但这些标准与试验特征无显著关联。
- 217项(75%)试验明确或间接排除老年患者,并观察到这类试验比例随时间增加的趋势。
- 仅1项试验(0.3%)仅纳入65岁及以上患者。
关键数值与推荐
- 年龄上限定义为85岁或以下,143/290(49%)项试验符合。
- 间接排除标准包括特定合并症(n = 114;39%)、依从性顾虑(n = 67;23%)、宽泛模糊的排除标准(n = 57;20%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess eligibility criteria that either explicitly or implicitly exclude older patients from randomized controlled trials (RCTs) in RA. METHODS: Our analysis included RCTs of pharmacological interventions registered with ClinicalTrials.gov and started between 2013 and 2022. Co-primary outcomes were proportions of trials with an upper age limit and the eligibility criteria indirectly increasing risk of the exclusion of older adults. RESULTS: A total of 143/290 (49%) trials had an upper age limit of 85 years or less. Multivariable analysis showed that the odds of an upper age limit were significantly lower in trials performed in the USA [adjusted odds ratio (aOR), 0.34; CI, 0.12-0.99; P = 0.04] and intercontinental trials (aOR, 0.4; CI, 0.18-0.87; P = 0.02). In total, 154/290 (53%) trials had at least one eligibility criterion implicitly excluding older adults. These included specific comorbidities (n = 114; 39%), compliance concerns (n = 67; 23%), and broad and vague exclusion criteria (n = 57; 20%); however, we found no significant associations between these criteria and trial characteristics. Overall, 217 (75%) trials either explicitly or implicitly excluded older patients; we also noted a trend towards increasing proportion of these trials over time. Only one trial (0.3%) enrolled solely patients aged 65 and older. CONCLUSION: Older adults are commonly excluded from RCTs in RA based on both age limits and other eligibility criteria. This seriously limits the evidence base for the treatment of older patients in clinical practice. Given the growing prevalence of RA in older adults, relevant RCTs should be more inclusive to them.
引用
- Mańko A, Raczkiewicz A, Górski A, et al. Exclusion of older adults from randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37243691. doi:10.1093/rheumatology/kead257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。